Mike Fedock, Executive Vice President and CFO of IQVIA, will present at the upcoming Barclays Global Healthcare Conference, highlighting the company’s strategic and financial outlook.
IQVIA Holdings Inc, a global leader in clinical research services, advanced analytics, and healthcare intelligence, has announced that its Executive Vice President and Chief Financial Officer, Mike Fedock, will participate in the upcoming Barclays 28th Annual Global Healthcare Conference. The presentation is scheduled to take place on Thursday, March 12, 2026, at 9:30 a.m. Eastern Time, bringing together leading executives, investors, and healthcare stakeholders for in-depth discussions on industry trends, financial performance, and strategic priorities shaping the future of global healthcare.
The Barclays Global Healthcare Conference is widely regarded as one of the most influential gatherings in the healthcare investment community. It serves as a platform for senior executives from biopharmaceutical companies, medical technology innovators, healthcare service providers, and data-driven organizations to share insights into market dynamics, regulatory developments, innovation pipelines, and long-term growth strategies. IQVIA’s participation underscores its prominent role at the intersection of healthcare data, technology, and life sciences innovation.
Leadership Perspective at a Pivotal Time
Mike Fedock’s presentation is expected to provide investors and analysts with a comprehensive overview of IQVIA’s financial performance, capital allocation priorities, and growth outlook. As Chief Financial Officer, Fedock plays a critical role in shaping the company’s global financial strategy, overseeing operational efficiencies, and ensuring disciplined investment in innovation and expansion initiatives. His remarks will likely highlight how IQVIA continues to capitalize on the growing demand for real-world evidence, decentralized clinical trials, and AI-powered healthcare analytics.
In an environment marked by rapid technological change, evolving regulatory requirements, and heightened focus on patient-centric care, IQVIA has positioned itself as a trusted partner to life sciences organizations worldwide. The company’s integrated solutions model allows clients to streamline clinical development, optimize commercial performance, and leverage data-driven intelligence to accelerate time-to-market for innovative therapies.
A live audio webcast of the presentation will be accessible through the Investor Relations section of IQVIA’s website, enabling shareholders and other interested parties to follow the discussion in real time. A replay will also be made available later the same day, ensuring broader access to the insights shared during the conference.
About IQVIA
Headquartered in the United States, IQVIA operates in more than 100 countries and employs approximately 93,000 professionals across healthcare, life sciences, data science, technology, and operational excellence disciplines. The company’s scale and global footprint enable it to support clients across the full lifecycle of medical innovation—from early-stage research and clinical development to commercialization and post-market surveillance.
IQVIA’s service offerings span three core areas:
- Clinical Research Services – Supporting pharmaceutical, biotechnology, and medical device companies in designing and executing clinical trials, including decentralized and hybrid trial models that enhance patient access and engagement.
- Commercial Insights and Strategy – Delivering actionable intelligence that helps life sciences companies optimize product launches, pricing strategies, and market positioning in increasingly competitive environments.
- Healthcare Intelligence and Advanced Analytics – Leveraging vast datasets and cutting-edge technology to generate insights that inform clinical decision-making, health policy development, and population health management.
At the heart of IQVIA’s capabilities is its proprietary IQVIA Connected Intelligence™ framework. This integrated approach combines high-quality healthcare data, advanced analytics, domain expertise, and AI-powered tools to transform complex information into practical, actionable insights. By linking clinical, commercial, and real-world data sources, IQVIA enables stakeholders to make more informed decisions that drive both business success and improved patient outcomes.
Responsible AI and Healthcare-Grade Innovation
A defining feature of IQVIA’s strategy is its emphasis on Healthcare-grade AI®. The company has invested heavily in artificial intelligence and machine learning technologies designed specifically for the highly regulated and sensitive healthcare sector. These AI-powered capabilities help clients identify patient populations, optimize trial site selection, predict treatment responses, and uncover emerging disease trends.
Importantly, IQVIA remains committed to responsible AI practices. The organization adheres to rigorous privacy standards, regulatory compliance frameworks, and patient safety principles. Its AI solutions are built with a focus on trust, scalability, and precision—qualities essential in an industry where data integrity and ethical stewardship are paramount.
With healthcare systems around the world grappling with aging populations, chronic disease burdens, and rising costs, the ability to harness AI effectively has become a strategic imperative. IQVIA’s combination of data assets, technological expertise, and healthcare domain knowledge positions it as a key enabler of digital transformation across the life sciences ecosystem.
Commitment to Patient Privacy and Data Protection
As one of the largest handlers of healthcare data globally, IQVIA places significant emphasis on protecting individual patient privacy. The company employs a wide array of privacy-enhancing technologies, de-identification methodologies, and secure data governance frameworks to safeguard sensitive information.
These safeguards allow IQVIA to generate insights at scale without compromising individual confidentiality. By analyzing aggregated and anonymized data, the company helps healthcare stakeholders detect disease patterns, assess treatment effectiveness, and identify optimal therapeutic pathways. This approach ensures that innovation and research can advance while maintaining strict adherence to privacy standards and ethical obligations.
IQVIA’s leadership in privacy protection has helped establish trust with pharmaceutical companies, regulators, healthcare providers, and patients alike. In a data-driven healthcare landscape, such trust is fundamental to sustaining innovation and collaboration.
Enabling the Path Toward Medical Breakthroughs
IQVIA’s comprehensive suite of services supports a broad range of stakeholders, including biotechnology firms, pharmaceutical manufacturers, medical device companies, academic researchers, government agencies, payers, and healthcare providers. By integrating clinical development expertise with commercial strategy and real-world evidence generation, the company accelerates the journey from scientific discovery to patient impact.
Through advanced analytics and predictive modeling, IQVIA enables clients to better understand disease progression, patient behavior, and treatment adherence patterns. These insights inform more effective clinical trial designs, targeted therapies, and personalized treatment approaches.
As healthcare continues to evolve toward precision medicine and value-based care models, IQVIA’s data-centric infrastructure provides a foundation for evidence-based decision-making. Its ability to connect disparate data sources—ranging from electronic health records to genomic data—creates a comprehensive view of the patient journey and unlocks new possibilities for innovation.
